Theriva biologics announces presentation of safety and pharmacokinetic data from cohort 1 of the phase 1b/2a clinical trial of syn-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients

- data presented at the 2023 tandem meetings: transplantation & cellular therapy meetings of astct and cibmtr -
TOVX Ratings Summary
TOVX Quant Ranking